Development of Two In Vitro ND1 -LHON Models for Evaluating Gene Therapy Efficacy
Investigative Ophthalmology & Visual Science · 2025-10-23 · 66 (13) · 34
DOI: 10.1167/iovs.66.13.34 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, published on 2025-10-23. Written by Xin Li and 5 co-authors. Institution: Department of Ophthalmology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, People's Republic of China. Major MEDLINE topics: Genetic Therapy, Optic Atrophy, Hereditary, Leber, NADH Dehydrogenase. Cited 1 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
The purpose of this study was to address the lack of effective treatments for NADH-ubiquinone oxidoreductase chain 1 (ND1)-related Leber hereditary optic neuropathy (LHON), this study aimed to (1) establish in vitro models mimicking mitochondrial dysfunction in LHON and (2) evaluate the therapeutic potential of recombinant adeno-associated virus (AAV)-mediated ND1 gene therapy (rAAV-ND1).
Methods
Two in vitro models were developed: (1) transmitochondrial cybrid cells carrying the m.3460G>A mutation in the ND1 gene; and (2) patient-derived induced pluripotent stem cells (iPSC)-differentiated retinal ganglion cells (RGCs). Mitochondrial function was assessed via measurements of oxygen consumption and adenosine triphosphate (ATP) production. The efficacy of rAAV-ND1 was tested by infecting both models to rescue mitochondrial deficiency.
Results
Our two LHON models - ND1-mutant cybrid cells and patient-derived iPSC-RGCs - successfully recapitulated characteristic mitochondrial dysfunction, demonstrating impaired oxidative phosphorylation and reduced ATP production. Through qPCR and subcellular fractionation analyses, we confirmed dose-dependent ND1 transgene expression and proper mitochondrial localization. Notably, rAAV2-ND1 treatment effectively restored mitochondrial function in both models: in ND1-cybrids, it recovered spare respiratory capacity to 85% of the control levels, enhanced complex I activity from 65.5% to 90.5%, and increased ATP production from 47.6% to 69.5%; whereas in ND1-RGCs, it also ameliorated bioenergetic deficits, partially reversing SRC reduction, and improving ATP-linked respiration.
Conclusions
The study demonstrates the utility of transmitochondrial cybrids and iPSC-derived RGCs as reliable in vitro models for studying ND1-related LHON. The rAAV-ND1 gene therapy effectively restored mitochondrial function, highlighting its potential as a treatment for LHON caused by ND1 mutations. These findings underscore the value of in vitro systems for evaluating therapies when robust animal models are unavailable.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, People's Republic of China.
Cite
APA
Li, X., Yuan, J., Chen, Z., Zhang, Y., Liu, Y., & Zhang, Y. (2025). Development of Two In Vitro ND1 -LHON Models for Evaluating Gene Therapy Efficacy. Investigative Ophthalmology & Visual Science, 66(13), 34. https://doi.org/10.1167/iovs.66.13.34
Vancouver
Li X, Yuan J, Chen Z, Zhang Y, Liu Y, Zhang Y. Development of Two In Vitro ND1 -LHON Models for Evaluating Gene Therapy Efficacy. Investigative Ophthalmology & Visual Science. 2025;66(13):34. doi:10.1167/iovs.66.13.34
BibTeX
@article{Li2025,
author = {Li, Xin and Yuan, Jun and Chen, Zhang and Zhang, Yue and Liu, Yuefeng and Zhang, Yong},
title = {Development of Two In Vitro ND1 -LHON Models for Evaluating Gene Therapy Efficacy},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
volume = {66},
number = {13},
pages = {34},
doi = {10.1167/iovs.66.13.34}
}
EUVIMED